Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandeep Dutta

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
Journal of Clinical Pharmacology|August 12, 2017
Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult SubjectsChih-Wei Lin, Sandeep Dutta, Bifeng Ding, et al.
Clinical Pharmacology in Drug Development|June 9, 2021
Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Omecamtiv MecarbilAshit Trivedi, Rajneet K Oberoi, Mia Mackowski, et al.
Clinical Pharmacology in Drug Development|October 11, 2021
Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy SubjectsAshit Trivedi, Winnie Sohn, Cheng-Pang Hsu, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Clinical Safety, Pharmacokinetics, and Pharmacodynamics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 in Healthy Volunteers and Elderly AdultsWei Liu, David A Katz, Charles Locke, et al.
The AAPS Journal|November 25, 2015
Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 StudiesSven Mensing, Akshanth R Polepally, Denise König, et al.
Journal of Cardiovascular Computed Tomography|October 9, 2012
Dual-energy CT and its potential use for quantitative myocardial CT perfusionAaron So, Jiang Hsieh, Suresh Narayanan, et al.
British Journal of Clinical Pharmacology|September 24, 2016
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trialsSven Mensing, Doerthe Eckert, Shringi Sharma, et al.
Clinical and Translational Science|August 20, 2021
Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic modelAshit Trivedi, Winnie Sohn, Priyanka Kulkarni, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's DiseaseJeffrey F Waring, Qi Tang, Weining Z Robieson, et al.
Biopharmaceutics & Drug Disposition|June 4, 2021
Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activatorAshit Trivedi, Rajneet K Oberoi, Mia Mackowski, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Journal of Clinical Pharmacology|August 12, 2017
Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult SubjectsChih-Wei Lin, Sandeep Dutta, Bifeng Ding, et al.
Clinical Pharmacology in Drug Development|June 9, 2021
Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Omecamtiv MecarbilAshit Trivedi, Rajneet K Oberoi, Mia Mackowski, et al.
Clinical Pharmacology in Drug Development|October 11, 2021
Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy SubjectsAshit Trivedi, Winnie Sohn, Cheng-Pang Hsu, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Clinical Safety, Pharmacokinetics, and Pharmacodynamics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 in Healthy Volunteers and Elderly AdultsWei Liu, David A Katz, Charles Locke, et al.
The AAPS Journal|November 25, 2015
Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 StudiesSven Mensing, Akshanth R Polepally, Denise König, et al.
Journal of Cardiovascular Computed Tomography|October 9, 2012
Dual-energy CT and its potential use for quantitative myocardial CT perfusionAaron So, Jiang Hsieh, Suresh Narayanan, et al.
British Journal of Clinical Pharmacology|September 24, 2016
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trialsSven Mensing, Doerthe Eckert, Shringi Sharma, et al.
Clinical and Translational Science|August 20, 2021
Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic modelAshit Trivedi, Winnie Sohn, Priyanka Kulkarni, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's DiseaseJeffrey F Waring, Qi Tang, Weining Z Robieson, et al.
Biopharmaceutics & Drug Disposition|June 4, 2021
Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activatorAshit Trivedi, Rajneet K Oberoi, Mia Mackowski, et al.
Pageof 12